Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Detailed Action
Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, 60, 92-93, and 112-113 are currently pending.
Election/Restriction
Applicant’s election without traverse of Group I (Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, and 60, drawn to compounds of Formula (I)) and the elected species:
PNG
media_image1.png
171
251
media_image1.png
Greyscale
in the reply filed on 9/28/2026 is acknowledged.
Claims 92-93, and 112-113 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected Group II or unelected species, there being no allowable generic or linking claim. Thus, Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, and 60 are being examined on the merits herein.
The requirement is deemed proper and is therefore made final.
The elected species was searched and found to be free of the art. Compounds of Formula 1 (according to both the Claim 1 and Claim 6 genera) were searched.
Information Disclosure Statement
The information disclosure statement(s) submitted on 3/19/2026 has not been signed “by an applicant or representative” as required (Page 4). Accordingly, the information disclosure statement has not been considered by the examiner.
Claim Objections
Claim 6 is objected to because of the following informalities:
Claim 6 is drawn to a compound of “Formula (I)” which is a different genus from the “Formula (I)” of Claim 1, which is a separate independent claim. Alternative naming is required to distinguish the different “Formula (I)” genera belonging to two different independent claims.
Appropriate correction is required.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 15 and 26 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
The latest amendments filed on 9/28/2026 strike “1” from the preambles. As amended, it is unclear which claim Claims 15 or 26 depend upon. In view of the “previously presented” status, and for the purpose of compact prosecution, the preamble of each claim is interpreted for examination to read as follows: “The compound of claim 1”.
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1, 3-9, 14-15, 19, 21, 26, 37, and 42 are rejected under 35 U.S.C. 103 as being unpatentable over Coates (WO2020146194, published 1/03/2020; 12/11/2024 IDS).
Coates teaches IL-17A inhibitors (Abstract). Coates teaches Example 24 on Page 106:
PNG
media_image2.png
209
331
media_image2.png
Greyscale
, which differs only from the elected species
PNG
media_image3.png
177
249
media_image3.png
Greyscale
as follows: (1) R2 of CH2O-cyclopropyl is instead CH2OCH3; and (2) the R1 of
PNG
media_image4.png
117
74
media_image4.png
Greyscale
is instead
PNG
media_image5.png
140
84
media_image5.png
Greyscale
, wherein m1 is 0, n is 1, R1b is thrice fluoro-substituted C1alkyl, m2 is 1, and the carbon to which (R1a)m3 is attached is missing.
Instant Claim 21 of the examined invention explicitly teaches the Coates CH2OCH3 is an acceptable Formula (I) group:
PNG
media_image6.png
30
50
media_image6.png
Greyscale
.
Coates does not teach an additional ring methylene between a ring nitrogen and the carbon possessing a haloalkyl substituent. However, compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups like the 2-imidazolinone ring of Coates and the instant 2-tetrahydropyrimidinone) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09. Therefore, one of skill in the art seeking to form an IL-17A inhibitor before the effective filing date of the present invention would have found it obvious to insert a methylene into the Coates ring, yielding a moiety as follows:
PNG
media_image7.png
99
67
media_image7.png
Greyscale
(ring group found in instant Claim 15). The same artisan would expect a successful inhibitor to result because homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”.
The elected species differs from the Coates compound by its R2 group, number of R1 ring members, and R1 substituent groups. No suggestion is made to modify the R1 ring to comport with that of the elected species or those species depicted in Claim 60. For these reasons, Claim 60 is not rejected.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
PROVISIONAL:
Claims 1, 3-9, 14-15, 19, 21, 26, 37, and 42 are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over Claims 1, 16, 22, 25, 32-34, 37-39, 43, 45, 48, 74, 76-80 (Claims according to 10/27/2026 response filed) of copending Application No. 18973307 (hereinafter referred to as Goldberg).
Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to a genus of IL-17 inhibitors of an instant formula
PNG
media_image8.png
315
459
media_image8.png
Greyscale
and a formula of the copending claims
PNG
media_image9.png
278
430
media_image9.png
Greyscale
. Goldberg recites similar functional groups to the instant with the narrower embodiments as follows:
R2 of
PNG
media_image10.png
64
307
media_image10.png
Greyscale
(Claim 16).
R3 of
PNG
media_image11.png
44
95
media_image11.png
Greyscale
(Claim 34)
R4 of
PNG
media_image12.png
84
387
media_image12.png
Greyscale
R1 can be
PNG
media_image13.png
68
78
media_image13.png
Greyscale
(Claim16), which differs from the examined embodiment of Claim 15
PNG
media_image14.png
67
69
media_image14.png
Greyscale
by a single methylene.
Regarding the single difference between the respective R1 groups, compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups like the 2-imidazolinone ring of Coates and the instant 2-tetrahydropyrimidinone) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09. Therefore, one of skill in the art seeking to form an IL-17 inhibitor according to the Goldberg formula would have found it obvious to insert a methylene into the ring, resulting in an R1 as shown in instant Claim 15:
PNG
media_image14.png
67
69
media_image14.png
Greyscale
. The same artisan would expect a successful inhibitor to result because homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”.
Copending claims drawn to methods of using the compounds require the existence of the similar homologous compounds over which the instant claims are rejected.
Since both applications teach IL-17 inhibitors of the same core, the examiner maintains that the aforementioned claims of the instant application are substantially overlapping in scope as discussed hereinabove and are prima facie obvious over the cited claims of Goldberg.
This is a provisional nonstatutory double patenting rejection.
NONPROVISIONAL:
Claims 1, 3-9, 14-15, 19, 21, 26, 37, and 42 are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over Claims 1-3, 5-9, 11-15, 18-20, and 22-24 of U.S. Patent No. 12215111 (hereinafter referred to as Goldberg).
Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to IL-17 inhibitors of the same core.
Goldberg teaches several compounds having the same core as those of the instant Formula (I). For example, Goldberg teaches the following compound in Claim 1:
PNG
media_image15.png
177
284
media_image15.png
Greyscale
, in which the following definitions of examined Formula (I) apply: R2 is
PNG
media_image16.png
36
26
media_image16.png
Greyscale
, R3 is
PNG
media_image17.png
67
85
media_image17.png
Greyscale
, R4 is a 5-membered heteroaryl with three heteroatoms selected from O and N, substituted by one R4a, which is a C1alkyl. Only R1 differs in that the compound above and those of Goldberg generally lack an additional ring methylene member. However, compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups like the 2-imidazolinone ring of Coates and the instant 2-tetrahydropyrimidinone) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09. Therefore, one of skill in the art seeking to form an IL-17 inhibitor homolog of the Goldberg compounds would find it obvious to insert a methylene into the ring, resulting in an R1 as shown in instant Claim 15:
PNG
media_image14.png
67
69
media_image14.png
Greyscale
or
PNG
media_image18.png
94
70
media_image18.png
Greyscale
, for example. The same artisan would expect a successful inhibitor to result because homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”.
Since both claim sets teach IL-17 inhibitors, the examiner maintains that the aforementioned claims of the instant application are substantially overlapping in scope as discussed hereinabove and are prima facie obvious over the cited claims of Goldberg.
Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, and 60 are rejected on the grounds of nonstatutory double patenting as being unpatentable over Claims 1-11, 13-14, 16-29, and 31-32 of U.S. Patent No. 12173007 (hereinafter referred to as Goldberg).
Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to IL-17 inhibitors.
Goldberg teaches several compounds which anticipate the instant Formula (I), the compounds listed in Claim 60, and the elected species. For example, the elected species is taught in Claim 1 of Goldberg:
PNG
media_image19.png
189
291
media_image19.png
Greyscale
Since both claim sets teach the same compounds, the examiner maintains that the aforementioned claims of the instant application are substantially overlapping in scope as discussed hereinabove and are anticipated by the cited claims of Goldberg.
Conclusion
No claim is allowable.
Inquiries
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Peckham whose telephone number is (703)756-4621. The examiner can normally be reached 8:30am - 4:30pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/RICHARD GRANT PECKHAM/Examiner, Art Unit 1627